Swedish Orphan Biovitrum AB (publ) Q3 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : So I have a few questions. I think I'll start on the high level here. So you've previously talked about midterm guidance of double-digit revenue growth. Does that continue to hold do you think? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 22, 2020 / 11:00AM, SOBIV.ST - Q3 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call And then, I guess, if you could potentially clarify a little bit. You've stated publicly a few times that you still have the same peak sales forecast for Doptelet. Now I guess, previously, you said that CIT was about half of it. And so I guess since some -- there are people who are asking if a write-down coming. Can you just clarify how you arrive there? I mean, how much -- I mean, are you still excluding CIT? Were you just being conservative before? And are you still being conservative now, if so?

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : No, that answered that question very well. And then the other question was on the midterm guidance for sales being...

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : Great. Great. And then the last high-level question would be, so obviously, I think you've had a fair amount of bad luck on a couple of recent events. But are there any lessons that can be learned from BD so far? Or...